New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists
- PMID: 15681814
- DOI: 10.1196/annals.1332.018
New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists
Abstract
Owing to improving preventative, diagnostic, and therapeutic measures for cardiovascular disease and a variety of cancers, the average ages of North Americans and Europeans continue to rise. Regrettably, accompanying this increase in life span, there has been an increase in the number of individuals afflicted with age-related neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and stroke. Although different cell types and brain areas are vulnerable among these, each disorder likely develops from activation of a common final cascade of biochemical and cellular events that eventually lead to neuronal dysfunction and death. In this regard, different triggers, including oxidative damage to DNA, the overactivation of glutamate receptors, and disruption of cellular calcium homeostasis, albeit initiated by different genetic and/or environmental factors, can instigate a cascade of intracellular events that induce apoptosis. To forestall the neurodegenerative process, we have chosen specific targets to inhibit that are at pivotal rate-limiting steps within the pathological cascade. Such targets include TNF-alpha, p53, and GLP-1 receptor. The cytokine TNF-alpha is elevated in Alzheimer's disease, Parkinson's disease, stroke, and amyotrophic lateral sclerosis. Its synthesis can be reduced via posttranscriptional mechanisms with novel analogues of the classic drug, thalidomide. The intracellular protein and transcription factor, p53, is activated by the Alzheimer's disease toxic peptide, Abeta, as well as by excess glutamate and hypoxia to trigger neural cell death. It is inactivated by novel tetrahydrobenzothiazole and -oxazole analogues to rescue cells from lethal insults. Stimulation of the glucagon-like peptide-1 receptor (GLP-1R) in brain is associated with neurotrophic functions that, additionally, can protect cells against excess glutamate and other toxic insults.
Similar articles
-
TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets.Curr Alzheimer Res. 2007 Sep;4(4):378-85. doi: 10.2174/156720507781788873. Curr Alzheimer Res. 2007. PMID: 17908040 Review.
-
Autophagy and apoptosis dysfunction in neurodegenerative disorders.Prog Neurobiol. 2014 Jan;112:24-49. doi: 10.1016/j.pneurobio.2013.10.004. Epub 2013 Nov 6. Prog Neurobiol. 2014. PMID: 24211851 Review.
-
Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.Biochem Soc Trans. 2011 Aug;39(4):891-7. doi: 10.1042/BST0390891. Biochem Soc Trans. 2011. PMID: 21787319
-
Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.J Neurol Sci. 2005 Jun 15;233(1-2):145-62. doi: 10.1016/j.jns.2005.03.012. J Neurol Sci. 2005. PMID: 15896810 Review.
-
Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.Neuromolecular Med. 2003;3(2):65-94. doi: 10.1385/NMM:3:2:65. Neuromolecular Med. 2003. PMID: 12728191 Review.
Cited by
-
Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders.Br J Pharmacol. 2012 Jul;166(5):1586-99. doi: 10.1111/j.1476-5381.2012.01971.x. Br J Pharmacol. 2012. PMID: 22519295 Free PMC article. Review.
-
Molecular Mechanisms behind Free Radical Scavengers Function against Oxidative Stress.Antioxidants (Basel). 2017 Jul 10;6(3):51. doi: 10.3390/antiox6030051. Antioxidants (Basel). 2017. PMID: 28698499 Free PMC article. Review.
-
The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype.Front Neurosci. 2024 Feb 15;18:1342944. doi: 10.3389/fnins.2024.1342944. eCollection 2024. Front Neurosci. 2024. PMID: 38426018 Free PMC article.
-
Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.Alzheimers Dement. 2014 Feb;10(1 Suppl):S62-75. doi: 10.1016/j.jalz.2013.12.011. Alzheimers Dement. 2014. PMID: 24529527 Free PMC article.
-
Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4.Alzheimers Dement. 2016 Jan;12(1):34-48. doi: 10.1016/j.jalz.2015.07.489. Epub 2015 Aug 29. Alzheimers Dement. 2016. PMID: 26327236 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous